HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a report released on ...

Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is expected to announce its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of ...

Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer ...

As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating ...

Shares of Spyre Therapeutics (SYRE) have gained 0.9% over the past four weeks to close the last trading session at $22.65, but there could still be a solid upside left in the stock if short-term price ...

New blinded preliminary BRTX-100 data described this past Saturday at prestigious "2025 Winners in Industry Innovations in MSK Health” presentation - - Among other positive preliminary data analyses, ...

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Dyne Therapeutics Inc. 4.43% $1.38B ...